Arcturus adds $50M Meiji investment as Q3 pipeline milestones stay on track
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)
2 stories
Meiji Seika Pharma bought a stake in Arcturus at a premium to fund OTC deficiency work and validate the LUNAR 2.0 platform, layered onto Q3 trial updates.
SEC filing (5)